Agile Therapeutics, Inc. Stock

Equities

AGRX

US00847L3087

Biotechnology & Medical Research

Market Closed - OTC Markets 03:56:36 2024-04-18 pm EDT 5-day change 1st Jan Change
0.37 USD +0.61% Intraday chart for Agile Therapeutics, Inc. -11.95% -81.03%
Sales 2024 * 36.84M Sales 2025 * 50.93M Capitalization 2.54M
Net income 2024 * 5M Net income 2025 * 13M EV / Sales 2024 * 0.07 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.05 x
P/E ratio 2024 *
0.47 x
P/E ratio 2025 *
0.34 x
Employees 19
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.56%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.61%
1 week-11.95%
Current month+8.82%
1 month-33.93%
3 months-76.58%
6 months-79.33%
Current year-81.03%
More quotes
1 week
0.36
Extreme 0.356
0.41
1 month
0.20
Extreme 0.2
0.61
Current year
0.20
Extreme 0.2
1.98
1 year
0.20
Extreme 0.2
7.00
3 years
0.20
Extreme 0.2
3 940.00
5 years
0.20
Extreme 0.2
9 530.40
10 years
0.20
Extreme 0.2
26 380.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 04-01-31
Director of Finance/CFO 57 10-11-30
Chief Tech/Sci/R&D Officer 58 20-08-16
Members of the board TitleAgeSince
Chief Executive Officer 65 04-01-31
Director/Board Member 68 16-07-27
Director/Board Member 67 14-11-17
More insiders
Date Price Change Volume
24-04-18 0.37 +0.61% 15,137
24-04-17 0.3678 -4.62% 119,671
24-04-16 0.3856 +4.10% 123,040
24-04-15 0.3704 +1.74% 35,158
24-04-12 0.364 -13.35% 78,790

Delayed Quote OTC Markets, April 18, 2024 at 03:56 pm EDT

More quotes
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.37
Average target price
-
Consensus